123 related articles for article (PubMed ID: 30776753)
1. Validation of LC-MS/MS methods for the determination of mirabegron and eight metabolites in human plasma in a paediatric population.
Meijer J; van den Berg T; Huls R; Hofstede V; Niesing W; van den Beld C; Krauwinkel W
J Pharm Biomed Anal; 2019 Apr; 167():155-160. PubMed ID: 30776753
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study.
Teijlingen Rv; Meijer J; Takusagawa S; Gelderen Mv; Beld Cv; Usui T
J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 887-888():102-11. PubMed ID: 22317789
[TBL] [Abstract][Full Text] [Related]
3. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
4. Determination of Mirabegron in rat plasma by UPLC-MS/MS after oral and intravenous administration.
Chen L; Zhang Y
Rev Assoc Med Bras (1992); 2019 Feb; 65(2):141-148. PubMed ID: 30892436
[TBL] [Abstract][Full Text] [Related]
5. Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist.
Takusagawa S; Yajima K; Miyashita A; Uehara S; Iwatsubo T; Usui T
Xenobiotica; 2012 Oct; 42(10):957-67. PubMed ID: 22509825
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
[TBL] [Abstract][Full Text] [Related]
7. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.
Eltink C; Lee J; Schaddelee M; Zhang W; Kerbusch V; Meijer J; van Marle S; Grunenberg N; Kowalski D; Drogendijk T; Moy S; Iitsuka H; van Gelderen M; Matsushima H; Sawamoto T
Int J Clin Pharmacol Ther; 2012 Nov; 50(11):838-50. PubMed ID: 22943933
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous quantification of mirabegron and vibegron in human plasma by HPLC-MS/MS and its application in the clinical determination in patients with tumors associated with overactive bladder.
Lou Y; Cheng M; Cao Q; Li K; Qin H; Bao M; Zhang Y; Lin S; Zhang Y
J Pharm Biomed Anal; 2024 Mar; 240():115937. PubMed ID: 38198885
[TBL] [Abstract][Full Text] [Related]
9. Translational science approach for assessment of cardiovascular effects and proarrhythmogenic potential of the beta-3 adrenergic agonist mirabegron.
Korstanje C; Suzuki M; Yuno K; Sato S; Ukai M; Schneidkraut MJ; Yan GX
J Pharmacol Toxicol Methods; 2017 Sep; 87():74-81. PubMed ID: 28434969
[TBL] [Abstract][Full Text] [Related]
10. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
[TBL] [Abstract][Full Text] [Related]
11. Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the β(3)-adrenoceptor agonist mirabegron in conscious rats with partial outflow obstruction.
Gillespie JI; Palea S; Guilloteau V; Guerard M; Lluel P; Korstanje C
BJU Int; 2012 Jul; 110(2 Pt 2):E132-42. PubMed ID: 22734512
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
Kobayashi M; Nukui A; Kamai T
Low Urin Tract Symptoms; 2018 May; 10(2):158-166. PubMed ID: 28009939
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of the Selective β3 -Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study.
Yamaguchi O; Marui E; Igawa Y; Takeda M; Nishizawa O; Ikeda Y; Ohkawa S
Low Urin Tract Symptoms; 2015 May; 7(2):84-92. PubMed ID: 26663687
[TBL] [Abstract][Full Text] [Related]
14. A validated LC-MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: application to a clinical pharmacokinetic study.
Furlong MT; Agrawal S; Hawthorne D; Lago M; Unger S; Krueger L; Stouffer B
J Pharm Biomed Anal; 2012 Jan; 58():130-5. PubMed ID: 21982905
[TBL] [Abstract][Full Text] [Related]
15. A drug safety evaluation of mirabegron in the management of overactive bladder.
Robinson D; Thiagamoorthy G; Cardozo L
Expert Opin Drug Saf; 2016 May; 15(5):689-96. PubMed ID: 26980445
[TBL] [Abstract][Full Text] [Related]
16. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
17. Mirabegron: A Review in Overactive Bladder Syndrome.
Deeks ED
Drugs; 2018 Jun; 78(8):833-844. PubMed ID: 29869204
[TBL] [Abstract][Full Text] [Related]
18. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder.
Blais AS; Nadeau G; Moore K; Genois L; Bolduc S
Eur Urol; 2016 Jul; 70(1):9-13. PubMed ID: 26876327
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported outcomes with the β
Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
[TBL] [Abstract][Full Text] [Related]
20. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
